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We recently showed that oxadiazoles have anti-Trypanosoma cruzi activity at micromolar concentrations.
These compounds are easy to synthesize and show a number of clear and interpretable structure–activity
relationships (SAR), features that make them attractive to pursue potency enhancement. We present here
the structural design, synthesis, and anti-T. cruzi evaluation of new oxadiazoles denoted 5a–h and 6a–h.
The design of these compounds was based on a previous model of computational docking of oxadiazoles
on the T. cruzi protease cruzain. We tested the ability of these compounds to inhibit catalytic activity of
cruzain, but we found no correlation between the enzyme inhibition and the antiparasitic activity of the
compounds. However, we found reliable SAR data when we tested these compounds against the whole
parasite. While none of these oxadiazoles showed toxicity for mammalian cells, oxadiazoles 6c (ﬂuorine),
6d (chlorine), and 6e (bromine) reduced epimastigote proliferation and were cidal for trypomastigotes of
T. cruzi Y strain. Oxadiazoles 6c and 6d have IC50 of 9.5 ± 2.8 and 3.5 ± 1.8 lM for trypomastigotes, while
Benznidazole, which is the currently used drug for Chagas disease treatment, showed an IC50 of
11.3 ± 2.8 lM. Compounds 6c and 6d impair trypomastigote development and invasion in macrophages,
and also induce ultrastructural alterations in trypomastigotes. Finally, compound 6d given orally at
50 mg/kg substantially reduces the parasitemia in T. cruzi-infected BALB/c mice. Our drug design resulted
in potency enhancement of oxadiazoles as anti-Chagas disease agents, and culminated with the identiﬁ-
cation of oxadiazole 6d, a trypanosomicidal compound in an animal model of infection.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
It is estimated that 10% of the whole Latin America population is
suffering from American trypanosomiasis or Chagas disease,
caused by the intracellular protozoan Trypanosoma cruzi.1,2 This
situation is alarming because there are no vaccines available and
the current treatment, which is only based on benznidazole
(Bdz), suffers limitations of efﬁcacy and toxicity.3,4
The T. cruzi cysteine-protease cruzain is an important drug tar-
get because it is expressed in all stages of the parasite life cycle and
play key roles as a virulence factor.5–8 An important proof-conceptll rights reserved.
: + 55 81 21267278.
br (J.M. dos Santos Filho).
e Imunologia, Universidadeof cruzain as a drug target is that its inhibitors efﬁciently eradicate
parasites in host-cells and substantially reduce parasitemia in dif-
ferent animal models of infection.9,10 The current status of cruzain
inhibitor research is quite promising because some of these lead
compounds are nonpeptidic and quite similar to drug-like com-
pounds, a step that is important for successful drug develop-
ment.10–12 Therefore, the identiﬁcation or structural optimization
of cruzain inhibitors is a promising avenue for Chagas disease
chemotherapy.
There is a substantial number of papers reporting oxadiazoles as
anti-parasitics. Oxadiazoles are frequently explored as bioisosters
of ester and amide functionalities. From this point of view, oxadi-
azoles are considered potential cysteine protease inhibitors be-
cause they are similar to peptide bonds.13–15 There are reports
showing that oxadiazoles are potent inhibitors versus cruzain of
T. cruzi and the cathepsin-L-like cysteine protease of Leishmania
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Figure 1. Structural design of oxadiazoles 5a–h and 6a–h as trypanocidal compounds.
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plore oxadiazoles as anti-T. cruzi agents. In 2009, we reported a
congener series of N-acylhydrazone 1,2,4-oxadiazoles, denoted
4a–h, exhibiting toxicity for trypomastigotes of T. cruzi Y strain.21
The oxadiazoles 4a–h showed minimal toxicity for mouse spleno-
cytes and a clear set of structure–activity relationships. A compu-
tational model of docking suggested oxadiazoles 4a–h might be
cruzain ligands. This model also suggested that the 4-hydroxy-
phenyl group near to the N-acylhydrazone is probably oriented
in a region of cruzain structure which is also the binding site for
highly-potent cruzain inhibitors.12 Based on this binding model,
we thought that structural modiﬁcations on 4-hydroxyphenyl
might lead to potency enhancement (Fig. 1).
The functional activity of oxadiazole 4a–h as trypanosomicidal
compounds led us to explore potency enhancement by molecular
modiﬁcation. For this study, we synthesized oxadiazoles 5a–h
and 6a–h, composed of the 3-aryl-1,2,4-oxadiazole-5-carbohydra-
zides of the previously identiﬁed anti-T. cruzi oxadiazoles 4a–h
with a replacement of 4-hydroxyphenyl group by 4-hydroxy-3-
methoxyphenyl for 5a–h and 1,3-benzodioxole for 6a–h. These
chemical replacements were selected due to the analogy between
these chemical groups (Fig. 1).22–24 Enhancement of anti-T. cruzi
activity in parasite cells was indeed achieved for oxadiazoles 6a–
h, furthermore these oxadiazoles impaired trypomastigote devel-
opment and invasion into host-cells, and mice orally treated with
oxadiazole 6d had a substantial reduction of parasitemia.
2. Results and discussion
2.1. Chemistry
The synthesis of compounds 5a–h and 6a–h is depicted in
Scheme 1 and is based on a method previously described by ourgroup.25 This starts with 4-substituted aryl amidoximes, which
are freshly prepared from commercially available nitriles; then
they react with methyloxalyl chloride yielding the 1,2,4-oxadiazol-
ic compounds in good yields. Further conversion of 1,2,4-oxadiaz-
ole methylesters into 1,2,4-oxadiazole hydrazides is achieved with
quantitative yields by reacting themwith hydrazine hydrate at 0 C
during 2 h.
These hydrazides, which are key intermediates in our research
to investigate the pharmacological properties of 1,2,4-oxadiaz-
oles,26 are of easy synthesis and produces the ﬁnal compounds,
N-acylhydrazones 5a–h and 6a–h. To establish a SAR between
our previously studied oxadiazoles (compounds 4a–h) and oxadi-
azoles 5a–h and 6a–h described here, we used the same substitu-
ents in both cases (R = H, CH3, F, Cl, Br, OCH3, OH, NO2,). The rp-
Hammet values for these substituents range from 0.37 for OH
to 0.78 for NO2, and therefore the electronic contribution of the
para-substituent on the phenyl group varies signiﬁcantly and al-
lows us to investigate the importance of each substituent. The
physical and spectroscopic data for the compounds 5a–h are de-
scribed here (experimental materials), while the spectral charac-
terization for 6a–h has been previously described.26
N-Acylhydrazones can yield a mixture of Z- and E-isomers,24 but
the 1H NMR analysis revealed that the E-isomers predominated
(>98%). The mild conditions we used for preparing N-acylhydra-
zones 5a–h and 6a–h (short reaction time and room temperature)
explain the predominance of the E-isomer in the crude products.
The X-ray analysis of 6f crystal obtained by crystallization from a
dimethylformamide solution exclusively produced the E-diaste-
reomer (Fig. 2), conﬁrming the 1H NMR data.
Quantum chemistry calculations (ab initio) suggested a planar
and E-geometry for compounds 6a–h and showed that two stable
conformers of this geometry are possible, differing only by
2.74 kcal/mol.26 The conformer of lowest energy is synperiplanar,
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other. The higher stability of this conformer is because of a non-
classical hydrogen bond between C@O and CH@N, like a ﬁve-mem-
ber ring. The antiperiplanar conformer has the carbonyl oxygen
and the iminic hydrogen in opposite sides (anti), and therefore
an intramolecular interaction is not possible. The conformations
we predicted by quantum chemistry and the observed one by X-
ray are different. The antiperiplanar conformer observed in the
crystalline structure can be explained. By X-ray diffraction, the
crystal structure of compound 6f presents one molecule of DMF
in the asymmetric unit. The position of the DMF molecule allows
its oxygen atom to interact with two hydrogen atoms of the NAH
from the imine group (CH@N) and the amide group (N–H) and it
provides stability for an antiperiplanar conformer.
2.2. Pharmacology
Once the compounds had been chemically characterized, we fo-
cused on evaluating their biological activity. All compounds were
evaluated against T. cruzi. We ﬁrst assayed the cell viability of
mouse splenocytes treated with oxadiazoles 5a–h and 6a–h. Given
that the compounds showed no toxicity in this assay, having an
LC50 higher than 100 lg/mL, they were evaluated against epim-
astigotes (axenic culture) and bloodstream trypomastigotes of Y
strain T. cruzi, using benznidazole (Bdz) as a control drug. The com-
pounds that showed IC50 values comparable to Bdz were further
selected for in vitro and in vivo assays. The ability of these com-
pounds to inhibit the activity of cruzain was also performed in par-
allel to the parasite cell assays. All compounds were initially tested
at 100 lM. For active compounds, a dose–response curve was
determined and the IC50 calculated. Table 1 summarizes the cruz-
ain and anti-T. cruzi activities for oxadiazoles 5a–h and 6a–h.None of the oxadiazoles 5a–h showed anti-T. cruzi activity. This
was an unexpected ﬁnding because compounds 5a–h only differ
from our early examined oxadiazoles (4a–h)21 by the introduction
of a 3-methoxy group. But we found potent trypanosomicidal
activities for oxadiazoles 6a–h. We ﬁrst noted that the halogenated
oxadiazoles 6c, 6d, and 6e were able to inhibit T. cruzi, with IC50
values quite similar to Bdz (Table 1). For example, oxadiazoles 6c
(ﬂuorine) and 6d (chlorine) have IC50 of 9.5 ± 2.8 and
3.5 ± 1.8 lM for Y strain trypomastigotes, quite similar to Benzni-
dazole (IC50 of 11.3 ± 2.8 lM) respectively. Neither oxadiazoles
6c, 6d, and 6e nor benznidazole affected the cell viability of mouse
splenocytes up to 100 lg/mL, while these compounds clearly affect
parasite proliferation (epimastigotes) and motility (trypomastig-
otes). The absence of toxicity for mouse splenocytes shows that
the cell effects of oxadiazoles and Bdz are speciﬁc for T. cruzi.
After conﬁrming that the oxadiazoles were able to kill T. cruzi
parasites, our next step was to understand how these compounds
affect the infection of host cells by trypomastigotes.27,28 We tested
oxadiazoles 6c, 6d, and 6e in an in vitro model of parasite infection
in macrophages. Macrophages were infected with Y strain trypom-
astigotes and then treated with compounds at 10 lg/mL, including
Bdz. Cells were analyzed by light microscopy and the percentage of
infected macrophages and the number of amastigotes were deter-
mined and compared to untreated infected cells (negative control)
and cells treated with benznidazole (positive control).
In untreated-infected macrophages (negative control), the per-
centage of infected cells is high (Figs. 3 and S1, Supplementary
data). As a result, trypomastigotes complete the intracellular cycle
into amastigotes, resulting in an average of almost 800 amastigotes
per 100 host-cells (Fig. 3).29 When 10 lg/mL of oxadiazoles 6c and
6d are added, the percentage of infected macrophages is signiﬁ-
cantly reduced when compared to untreated cells. Oxadiazole 6e,
Figure 2. (A) General representation of the syn and anti conformers for oxadiazoles 6a-h. (B) Top: structure of 6f determined by X-ray analysis (ORTEP-3 view, displacement
ellipsoids are drawn at a 50% level), highlighting the E-geometry and the anti arrangement. The bottom highlights that the molecule is entirely planar.
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no activity in these assays. When 10 lg/mL of oxadiazoles 6c or 6d
are added at the moment of infection, the number of infected cells
is lower than untreated-infected macrophages (Fig. S2 Supplemen-
tary data). This suggests that oxadiazoles 6c and 6d impair trypo-
mastigote invasion into host-cells. The oxadiazoles 6c and 6d
arrested trypomastigote development and invasion of macro-
phages. Therefore, potency enhancement of anti-T. cruzi activity
was achieved for oxadiazoles 6a–h when compared to our previ-
ously studied oxadiazoles 4a–h.21
We also investigated the ability of these compounds to inhibit
the recombinant cysteine protease of T. cruzi, cruzain.18 As seen
in Table 1, oxadiazoles 5d, 5e and 6e showed high-afﬁnity for cruz-
ain (IC50 from 40 to 200 nM). Cruzain inhibition by these three oxa-
diazoles was higher when they were pre-incubated with the
enzyme, consistent with a covalent-mechanism of inhibition. N-
Acylhydrazones such as compounds 5d and 5e may undergo Mi-
chael-addition reactions, yielding covalent adducts with cruzain.30
Other oxadiazoles of the series 5a–h and 6a–h did not show signif-
icant cruzain inhibition at 100 lM, so no SAR could be drawn. The
cruzain inhibition observed for oxadiazoles 5d, 5e and 6e was notdue to nonspeciﬁc binding. The assay was repeated in the absence
and the presence of 0.1% Triton X-100.18 The level of cruzain inhi-
bition did not vary among these conditions, suggesting that en-
zyme inhibition is not due to compound aggregation. Since there
is no reliable correlation between cruzain inhibition and trypanos-
omicidal properties, the trypanosomicidal effects of oxadiazoles
are only in part due to cruzain inhibition, other targets and bio-
chemical pathways must be involved.
To further investigate the mechanism of action of oxadiazoles
6c and 6d, ultrastructural alterations in bloodstream trypomastig-
otes were analyzed. Electron micrographs are shown in Figure 4. In
comparison to untreated parasites, trypomastigotes incubated
with 6c and 6d had membrane protrusions in about 80% of cells.
Oxadiazoles 6c and 6d caused mitochondria degeneration, Golgi
apparatus and endoplasmic reticulum disorganization, followed
by kinetoplast enlargement. When infected macrophages were
treated with 3.5 lM of oxadiazole 6d, we could observe that oxadi-
azole 6d targets mitochondria, causing fragmentation as well as
the formation of atypical vacuoles which contain mitochondrial
components (Fig. 5). High-afﬁnity cruzain inhibitors, such as pep-
tide K777, are believed to induce structural alterations in Golgi
Table 1
Cruzain and anti-T. cruzi activities
Compound R % Cruzain inhibition 100 lMa Y strain T. cruzi IC50 lM ( ± SD) Mouse splenocytes
Trypomastigotesb Epimastigotesc LC50d (lg/mL)
N
H
N
O
N
NO
RO
H
O
5a H 47 ND ND >100
5b CH3 14 ND ND >100
5c F 63 ND ND >100
5d Cl 92 (0.04) ND ND >100
5e Br 100 (0.2) ND ND >100
5f NO2 47 ND ND >100
5g OH 25 ND ND >100
5h CH3O 35 ND ND >100
O
O
N
H
N
O
N
NO
R
6a H 32 ND ND >100
6b CH3 49 ND ND >100
6c F 34 9.5 ( ± 2.8) 12.2 ( ± 7.6) >100
6d Cl 42 3.5 ( ± 1.8) 7.5 ( ± 4.8) >100
6e Br 95 (0.03) 13.4 ( ± 1.8) 14.0 ( ± 5.4) >100
6f NO2 NT ND ND >100
6g OH 17 ND ND >100
6h CH3O 44 ND ND >100
Bdze — — 11.3 ( ± 1.8) 7.5 ( ± 2.1) —
GVe — — — — 0.11
a Cruzain inhibition after a 10 min pre-incubation with the inhibitor. The results represent the average of duplicates. Values in parenthesis represent IC50 values in lM,
which were determined based on at least 9 compound concentrations in duplicate.
b Determined after 24 h of incubation of trypomastigotes with the compounds. Values were calculated from ﬁve concentrations using data obtained from at least two
independent experiments (SD given in parenthesis).
c Determined after 5 days of incubation of epimastigotes with the compounds. IC50 was calculated from ﬁve concentrations using data obtained from at least two
independent experiments (SD given in parenthesis).
d Toxicity for splenocytes of BALB/c mouse after 24 h of incubation in the presence of the compounds.
e Bdz = Benznidazole; GV = Gentian Violet. Nd., not determined, due to the lack of activity in the tested concentration. SD = standard deviation.
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into lysosomes/reservosomes.31 Alterations of mitochondria and
kinetoplast are not observed for well-known cruzain inhibi-
tors.31,32 These information differed from those observed here for
oxadiazoles 6c and 6d. What we observed is that oxadiazoles sub-
stantially alter the mitochondrial morphology, therefore proteins
involved in parasite metabolism and bioenergetics might be the
molecular targets for oxadiazoles. Instead of attempting to identify
these target proteins, we decided to evaluate whether these com-
pounds reduce blood parasitemia in T. cruzi-infected mice.
To determine the maximum tolerated dose (MTD), single oral
treatment of oxadiazole 6d to uninfected BALB/c mice (n = 3/
group) at doses of 25, 50, and 100 mg/kg was performed. Mice trea-
ted with 6d appeared normal and no mortality was observed. We
also measured serum biochemical components in uninfected mice
treated with 6d (Table S1). In comparison to untreated and unin-
fected mice, treatment with 6d did not systematically change ser-
um components, suggesting the toxicity of these oxadiazoles is not
a major concern. Based on this, oxadiazoles 6c and 6dwere admin-
istrated at dose of 50 mg/kg to infected mice.
BALB/c mice were infected with Y strain trypomastigotes33
and treated or not with 6c, 6d, and Bdz. In untreated, infected
mice, blood parasitemia was observed after day 8 of parasite
inoculation and peaked on day 10 (Fig. 6). Benznidazole (Bdz) gi-ven orally at 100 mg/kg once a day for 5 days (starting from day
5 after infection) almost eradicated blood parasitemia. Com-
pound 6d substantially reduced blood parasitemia (p <0.001)
compared to untreated infected mice. Compound 6c did not re-
duce parasitemia as much as compound 6d, as expected based
on its lower potency. Compound 6e was not tested due to low
solubility.
N-Acylhydrazones are known for their in vitro trypanosomicidal
and cruzain inhibition effects.34–37 However, very few N-acylhy-
drazones that are effective in reducing in vivo infection have been
identiﬁed.38 One method for increasing the efﬁcacy of anti-T. cruzi
N-acylhydrazones is through the combination with oxadiazole
chemistry.19–21 From our past studies, we discovered that N-acyl-
hydrazones derived from 1,2,4-oxadiazole chemistry were less po-
tent trypanosomicidal agents than benznidazole, but at least they
were more selective for parasite than to mammalian cells.21 Here,
our main aim was to improve the cidal potency by molecular mod-
iﬁcation. We knew from past SAR model that the N-acylhydrazone
motif is more suitable and tolerates molecular modiﬁcation. In
view of this, we planned compounds 5a–h and 6a–h. This struc-
tural design was successful and led us to identify the anti-T. cruzi
oxadiazole denoted 6d.
We believe that compound 6dmerits further chemical optimiza-
tion because: (a) it has a selectivity window of at least 50 (host cell
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Figure 3. Oxadiazoles impair T. cruzi trypomastigote development in macrophages.
The percentage of infected macrophages (A) and the mean number of amastigotes/
infected cell (B) are higher in untreated infected controls than in cultures treated
with 10 lg/mL of test-inhibitors 6c or 6d. Bdz is benznidazole. Experiment done in
triplicate. Standard deviations are shown as error bars. ⁄⁄⁄, p <0.001; ⁄, p <0.05.
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oral treatment; (c) at a dose of 50 mg/kg (140 lmol/kg) parasitemia
was reduced in vivo; (d) 6d is a low-molecular weight, achiral, and
nonpeptidic compound. These functional properties and chemical
features are desirable for a Chagas disease drug candidate.39
3. Conclusions
From our past studies, oxadiazoles were less potent cidals than
benznidazole, but they were more selective for parasite versus
mammalian cells. Here, our effort was to improve their cidal po-
tency by molecular modiﬁcation of substituents. To this end, try-
panosomicidal properties as well cruzain inhibition of 3-aryl-
1,2,4-oxadiazole-5-carbohydrazides containing a 4-hydroxy-3-
methoxyphenyl 5a–h or 1,3-benzodioxole 6a–h were determined.
Oxadiazole 6d, which features a 1,3-benzodioxole group near to
the N-acylhydrazone was identiﬁed as the most potent and selec-
tive trypanosomicidal compound among them, and endowed with
efﬁcacy in reducing blood parasitemia in a mouse model of acute
infection. The efﬁcacy observed for oxadiazole 6d in in vitro and
in vivo models of infection argues favorably for oxadiazoles as
antiparasitic agents and therefore the synthetic redesign of vari-
ant forms of oxadiazole 6d is worthy.
4. Experimental section
4.1. Chemistry
Melting points were determined on a Gallenkamp capillary
apparatus and are uncorrected. Infrared spectra were determinedusing KBr discs on a Perkin–Elmer Paragon 500 FT-IR spectrometer.
1H NMR spectra were determined on a Bruker DPX-200 spectrom-
eter, with chemical shifts d reported in ppm unities relative to the
internal standard TMS, using DMSO-d6 as solvent. Mass spectral
were determined by using a Finnigan mass spectrometers model
MAT 8200 for low resolution mass spectrometry (MS) and the
MAT 95 for high resolution mass spectrometry (HRMS). Values
for HRMS lie within the permitted limit intervals with resolution
of 10,000. The reactions were monitored by thin layer chromatog-
raphy (TLC), performed on plates prepared with a 0.2 mm thick sil-
ica gel 60 (PF-254 with gypsum, Merck). The developed
chromatograms were visualized under ultraviolet light at 254–
265 nm. For column chromatography, silica gel 60 (230–400 mesh,
Merck) was used. All common laboratory chemicals were pur-
chased from commercial sources and used without previous puri-
ﬁcation. Crystallographic data for compound 6f can be obtained
free of charge at the Cambridge Crystallographic Data Centre
(CCDC, deposit number 870707, www.ccdc.cam.ac.uk/data_re-
quest/cif).
4.1.1. General procedure for preparation of compounds 5a–h
To a stirred suspension of 0.01 mol of appropriate hydrazide in
5 mL of ethanol, 3–4 drops of concentrated sulfuric acid were
added, changing the mixture to a clear solution. Then, vanillin
(0.01 mol) previously dissolved in 5 mL of ethanol was added to
the mixture at room temperature. After few seconds, a colored so-
lid precipitated and the mixture was stirred for 10 min before the
addition of 10 mL of water. After vacuum ﬁltration, the solid was
washed with cold water/ethanol 1:1 and then with cold water.
Recrystallization from dioxane/water mixture afforded the crystal-
line solids. Yields, melting points, spectroscopic and spectrometric
data are listed below for each compound.
4.1.1.1. 3-Phenyl-N0-[(4-hydroxy-3-methoxyphenyl)methylene]-
1,2,4-oxadiazole-5-carbohydrazide (5a). Yield: 91%; Mp
216 C (from dioxane/H2O); IR (KBr, cm1): m = 3494 (br O–H),
3448 (N–H, acyl hydrazone), 3190 (C–H, imine), 1674 (C@O),
1594 (C@N, imine), 1516 (C@N, heterocyclic). 1H NMR (200 MHz,
DMSO-d6) d: 12.6 (s, 1H, CONH), 9.71 (s, 1H, OH), 8.48 (s, 1H,
N@CH), 8.09–8.06 (m, 2H, ortho to oxadiazole ArH), 7.63–7.59
(m, 3H, meta/para to oxadiazole ArH), 7.31 (s, 1H, 2 to hydrazone
ArH), 7.11 (d, 1H, 3J = 8.3 Hz, 6 to hydrazone ArH), 6.84 (d, 1H, 3J
7.8 Hz, 5 to hydrazone ArH), 3.82 (s, 3H, OCH3). MS (m/z,%): 338
(M+, 100), 192 (M-phenyloxadiazole, 14), 164 (192-CO, 6), 149
(192-HNCO, 43), 136 (164-N2, 70). HRMS for C17H14N4O4 calcd
(found): 338.10151 (338.10238).
4.1.1.2. 3-(4-Methylphenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5b). Yield:
92%; Mp 213 C (from dioxane/H2O); IR (KBr, cm1): m = 3479 (br
O–H; N–H, acyl hydrazone), 3181 (C–H, imine), 1702 (C@O),
1607 (C@N, imine), 1515 (C@N, heterocyclic). 1H NMR (200 MHz,
DMSO-d6) d: 12.6 (s, 1H, CONH), 9,70 (s, 1H, OH), 8.47 (s, 1H,
N@CH), 7.97 (d, 2H, 3J = 8.1 Hz, ortho to oxadiazole ArH), 7.41 (d,
2H, 3J = 8.1 Hz, meta to oxadiazole ArH), 7.31 (d, 1H, 4J = 1.7 Hz, 2
to hydrazone ArH), 7.10 (dd, 1H, 4J = 1.7 Hz, 3J = 8.4 Hz, 6 to hydra-
zone ArH), 6.84 (d, 1H, 3J = 8.4 Hz, 5 to hydrazone ArH), 3.82 (s, 3H,
OCH3), 2.38 (s, 3H, CH3). MS (m/z,%): 352 (M+, 100), 192 (M-phen-
yloxadiazole, 14), 164 (192-CO, 3), 149 (192-HNCO, 60), 136 (164-
N2, 78). HRMS for C18H16N4O4 calcd (found): 352.11716
(352.11712).
4.1.1.3. 3-(4-Fluorophenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5c). Yield:
90%; Mp 216 C (from dioxane/H2O); IR (KBr, cm1): m = 3486 (br
O–H), 3446 (N–H, acyl hydrazone), 3197 (C–H, imine), 1677
Figure 4. Oxadiazoles induce ultrastructural changes in bloodstream trypomastigotes. Using SEM, we observed plasma membrane protrusions (arrows) in cells treated with
compounds 6c (30 lM; D) or 6d (10 lM; G); untreated cells (A). Using TEM, untreated trypomastigotes highlighting Golgi apparatus and mitochondria (B) and kinetoplast (C).
In cells treated with 6c (9.5 lM, E, F) or 6d (3.5 lM, H, I), we observed alterations in Golgi apparatus (E), mitochondria (F), membranes of endoplasmic reticulum (H), and
kinetoplast (I). GA = Golgi apparatus; ⁄ = Mitochondria; ER = endoplasmic reticulum; K = kinetoplast.
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(200 MHz, DMSO-d6) d: 12.6 (s, 1H, CONH), 9,70 (s, 1H, OH), 8.47
(s, 1H, N@CH), 8.13 (dd, 2H, 4JF-H = 5.2 Hz, 3J = 8.8 Hz, ortho to oxa-
diazole ArH), 7.46 (t, 2H, J = 8.8 Hz, meta to oxadiazole ArH), 7.3 (d,
1H, 4J = 1.3 Hz, 2 to hydrazone ArH), 7.11 (dd, 1H, 4J = 1.3 Hz,
3J = 8.2 Hz, 6 to hydrazone ArH), 6.84 (d, 1H, 3J = 7.9 Hz, 5 to hydra-
zone ArH), 3.82 (s, 3H, OCH3). MS (m/z,%): 356 (M+, 100), 192 (M-
phenyloxadiazole, 14), 164 (192-CO, 6), 149 (192-HNCO, 68), 136
(164-N2, 72). HRMS Calcd for C17H13N4O4F calcd (found):
356.09208 (356.09178).
4.1.1.4. 3-(4-Chlorophenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5d). Yield:
88%; Mp 219 C (from dioxane/H2O); IR (KBr, cm1): m = 3501 (br
O–H), 3446 (N–H, acyl hydrazone), 3223 (C–H, imine), 1678
(C@O), 1591 (C@N, imine), 1517 (C@N, heterocyclic). 1H NMR
(200 MHz, DMSO-d6) d: 12.6 (s, 1H, CONH), 9.71 (s, 1H, OH), 8.47
(s, 1H, N@CH), 8.09 (d, 2H, 3J = 8.5 Hz, ortho to oxadiazole ArH),
7.69 (d, 2H, J = 8.1 Hz, meta to oxadiazole ArH), 7.30 (d, 1H,
4J = 1.3 Hz, 2 to hydrazone ArH), 7.11 (dd, 1H, 4J = 1.3 Hz,
3J = 9.8 Hz, 6 to hydrazone ArH), 6.84 (d, 1H, 3J = 8.1 Hz, 5 to hydra-
zone ArH), 3.82 (s, 3H, OCH3). MS (m/z,%): 372/375 (M+, 100/34),
192 (M-phenyloxadiazole, 21), 164 (192-CO, 7), 149 (192-HNCO,
97), 136 (164-N2, 98). HRMS for C17H13N4O4Cl calcd (found):
372.06253 (372.06334).4.1.1.5. 3-(4-Bromophenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5e). Yield:
88%; Mp 212 C (from dioxane/H2O); IR (KBr, cm1): m = 3329 (br
O–H), 3217 (N–H, acyl hydrazone), 3190 (C–H, imine), 1674
(C@O), 1583 (C@N, imine), 1516 (C@N, heterocyclic). 1H NMR
(200 MHz, DMSO-d6) d: 12.7 (s, 1H, CONH), 9.70 (s, 1H, OH), 8.47
(s, 1H, N@CH), 8.02 (d, 2H, 3J = 8.5 Hz, ortho to oxadiazole ArH),
7.83 (d, 2H, J = 8.5 Hz, meta to oxadiazole ArH), 7.30 (d, 1H,
4J = 1.3 Hz, 2 to hydrazone ArH), 7.11 (dd, 1H, 4J = 1.3 Hz,
3J = 8.2 Hz, 6 to hydrazone ArH), 6.84 (d, 1H, 3J = 7.8 Hz, 5 to hydra-
zone ArH), 3.82 (s, 3H, OCH3). MS (m/z,%): 416/418 (M +, 59/59),
192 (M-phenyloxadiazole, 21), 164 (192-CO, 7), 149 (192-HNCO,
100), 136 (164-N2, 97). HRMS for C17H13N4O4Br calcd (found):
416.01202 (416.01187).
4.1.1.6. 3-(4-Nitrophenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbohydrazide (5f). Yield:
91%; Mp 383 C (from dioxane/H2O); IR (KBr, cm1): m = 3490 (br
O–H), 3280 (N–H, acyl hydrazone), 1697 (C@O), 1596 (C@N,
imine), 1513 (C@N, heterocyclic). 1H NMR (200 MHz, DMSO-d6)
d: 12.8 (s, 1H, CONH), 9.70 (s, 1H, OH), 8.48 (s, 1H, N@CH), 8.46
(d, 2H, 3J = 9.3 Hz, meta to oxadiazole ArH), 8.34 (d, 2H,
3J = 8.8 Hz, ortho to oxadiazole ArH), 7.31 (d, 1H, 4J = 1.3 Hz, 2 to
hydrazone ArH), 7.12 (dd, 1H, 4J = 1.3 Hz, 3J = 8.3 Hz, 6 to hydra-
zone ArH), 6.85 (d, 1H, 3J = 8.3 Hz, 5 to hydrazone ArH), 3.82 (s,
Figure 5. Oxadiazole 6d induces structural changes in intracellular amastigotes. (A and B) TEM of untreated cells highlighting nucleus (N), kinetoplast (K), mitochondria (M)
and Golgi apparatus (GA). (C and D) in cells treated with 3.25 lM of 6d we observed alterations in membrane (black arrow), degradation of mitochondria (white arrow) as
well atypical mitochondrial vacuoles (black stars). Scale of 2.0 (A), 1.0 (B), 0.5 (C), and 0.2 lm (D).
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18), 164 (192-CO, 6), 149 (192-HNCO, 73), 136 (164-N2, 62). HRMS
for C17H13N5O6 calcd (found): 383.08658 (383.08753).
4.1.1.7. 3-(4-Hydroxyphenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5g). Yield:
99%; Mp 264 C (from dioxane/H2O); IR (KBr, cm1): m = 3518, 3499
(O–H), 3293 (N–H, acyl hydrazone), 1693 (C@O), 1596 (C@N,
imine), 1512 (C@N, heterocyclic). 1H NMR (200 MHz, DMSO-d6)
d: 12.6 (s, 1H, CONH), 10.2 (s, 1H, para to oxadiazole OH), 9.69 (s,
1H, OH), 8.46 (s, 1H, N@CH), 7.91 (d, 2H, 3J = 8.8 Hz, ortho to oxa-
diazole ArH), 7.30 (d, 1H, 4J = 1.3 Hz, 2 to hydrazone ArH), 7.11 (dd,
1H, 4J = 1.5 Hz, 3J = 8.2 Hz, 6 to hydrazone ArH), 6.94 (d, 2H,
3J = 8.8 Hz, meta to oxadiazole ArH), 6.84 (d, 1H, 3J = 8.2 Hz, 5 to
hydrazone ArH), 3.82 (s, 3H, OCH3). MS (m/z,%): 354 (M +, 100),
192 (M-phenyloxadiazole, 8), 164 (192-CO, 3), 149 (192-HNCO,
32), 136 (164-N2, 42). HRMS for C17H14N4O5 calcd (found):
354.09642 (354.09733).
4.1.1.8. 3-(4-Methoxyphenyl)-N0-[(4-hydroxy-3-methoxyphenyl)-
methylene]-1,2,4-oxadiazole-5-carbo hydrazide (5h). Yield:
97%; Mp 221 C (from dioxane/H2O); IR (KBr, cm1): m = 3500–3000 (br O–H), 3415 (N–H, acyl hydrazone), 1677 (C@O), 1597
(C@N, imine), 1512 (C@N, heterocyclic). 1H NMR (200 MHz,
DMSO-d6) d: 12.6 (s, 1H, CONH), 9.70 (s, 1H, OH), 8.47 (s, 1H,
N@CH), 8.02 (d, 2H, 3J = 8.9 Hz, ortho to oxadiazole ArH), 7.31 (d,
1H, 4J = 1.3 Hz, 2 to hydrazone ArH), 7.15 (d, 2H, 3J = 8.6 Hz, meta
to oxadiazole ArH), 7.11 (dd, 1H, 4J = 1.3 Hz, 3J = 8.3 Hz, 6 to hydra-
zone ArH), 6.84 (d, 1H, 3J = 8.3 Hz, 5 to hydrazone ArH), 3.84 (s, 3H,
para to oxadiazole OCH3), 3.82 (s, 3H, OCH3). MS (m/z,%): 368 (M+,
100), 192 (M-phenyloxadiazole, 10), 164 (192-CO, 4), 149 (192-
HNCO, 35), 136 (164-N2, 42). HRMS for C18H16N4O5 calcd (found):
368.11207 (368.11232).
4.2. Animals
Female BALB/c mice (6–8 weeks old) were supplied by the ani-
mal breeding facility at Centro de Pesquisas Gonçalo Moniz (Fun-
dação Oswaldo Cruz, Bahia, Brazil) and maintained in sterilized
cages under a controlled environment, receiving a balanced diet
for rodents and water ad libitum. All experiments were carried
out in accordance with the recommendations of Ethical Issues
Guidelines, and were approved by the local Animal Ethics
Committee.
Figure 6. Oxadiazole 6d substantially reduces parasitemia in mice. Female BALB/c mice were infected with 104 Y strain trypomastigotes. Five days after infection, mice were
treated orally with compounds 6c and 6d in one daily dose of 50 mg/kg or Benznidazole (Bdz, at 100 mg/kg), during ﬁve consecutive days. Parasitemia was monitored by
counting the number of trypomastigotes in fresh blood samples. Values represent the mean ± SEM of six mice per group. Two independent experiments, data are from one
experiment. ⁄⁄⁄, p <0.001 compared to untreated-infected group (vehicle).
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Epimastigotes of T. cruzi (Y strain) were maintained at 26 C in
LIT medium (Liver Infusion Tryptose) supplemented with 10% fetal
bovine serum (FBS) (Cultilab, Campinas, SP, Brazil), 1% hemin (Sig-
ma Co, St. Louis, MO, USA), 1% R9 medium (Sigma Co), and 50 lg/
mL gentamycin (Novafarma, Anápolis, GO, Brazil). Bloodstream
trypomastigotes forms of T. cruzi were obtained from supernatants
of LLC-MK2 cells previously infected and maintained in RPMI-1640
medium (Sigma Co.) supplemented with 10% FBS, and 50 lg/mL
gentamycin at 37 C and 5% CO2.
4.4. Cruzain inhibition
Cruzain activity was measured by monitoring the cleavage of
the ﬂuorogenic substrate Z-Phe-Arg-aminomethylcoumarin (Z-
FR-AMC), as previously described.18 All assays were performed in
96-well plate format, in a ﬁnal volume of 200 lL, in sodium acetate
0.1 M (pH 5.5), in the presence of 5 mM dithiothreitol (DTT) and
0.01% Triton X-100, except for evaluation of detergent-sensitivity,
when inhibition was also evaluated in 0% and 0.1% Triton for com-
parison. The enzyme was present at the ﬁnal concentration of
0.4 nM and the substrate at 2.5 lM (Km = 2 lM). All assays were
performed in duplicate and followed for 5 min, and cruzain activity
was calculated based on initial rates of substrate cleavage com-
pared to a DMSO control. All compounds were dissolved in DMSO.
The initial screen was performed at 100 lM of each compound.
Compounds were ﬁrst evaluated for time-dependence by compar-
ing percentages of enzyme inhibition by a compound with or with-
out pre-incubation with enzyme for 10 min. During the pre-
incubation step, cruzain and compound concentrations were 10-
fold higher than in the ﬁnal assay. Since compounds were observed
to be time-dependent, consistently with a covalent mode of inhibi-
tion, all subsequent assays were performed with a 10 min pre-
incubation. Compounds which inhibited over 50% of cruzain activ-
ity at 100 lM had their IC50 determined and were further evalu-ated for detergent-sensitivity. Dose–response curves were
determined based on at least nine compounds concentrations,
varying from 100 lM to 0.1 nM in fourfold dilutions. Data was ana-
lyzed with Prism 4 (GraphPad) employing non-linear regression.
4.5. Cytotoxicity to mouse splenocytes
Splenocytes obtained from BALB/c mice were placed into 96-
well plates at a cell density of 5  106 cells/well in RPMI-1640
medium supplemented with 10% of FBS and 50 lg mL1 of genta-
mycin. Each test inhibitor was used in ﬁve concentrations (1.23,
3.70, 11.11, 33.33, and 100 lg mL1) in triplicate. To each well,
an aliquot of test inhibitor suspended in DMSO was added. Con-
trols included wells only containing either solvent (untreated
cells) or gentian violet (positive control). The plate was incubated
for 24 h at 37 C and 5% CO2. After incubation, 1.0 lCi of 3H-thy-
midine (Perkin Elmer, Waltham, USA) was added to each well,
and the plate was returned to the incubator. The plate was then
transferred to a beta-radiation counter (Multilabel Reader, Fin-
land), and the percent of 3H-thymidine was determined. Cell via-
bility was measured as the percent of 3H-thymidine incorporation
for treated-cells in comparison to untreated cells. LD50 values
were calculated using data-points gathered from two indepen-
dent experiments.
4.6. Antiproliferative activity for epimastigotes
Epimastigotes were counted in a hemocytometer and then dis-
pensed into 96-well plates at a cell density of 106 cells/well. Test
inhibitors, dissolved in DMSO, were diluted into ﬁve different con-
centrations (1.23, 3.70, 11.11, 33.33, and 100 lg/mL) and added to
the respective wells in triplicate. The plate was incubated for
5 days at 26 C, and aliquots of each well were collected and the
number of viable parasites were counted in a Neubauer chamber,
and compared to untreated parasite culture. IC50 calculation was
carried out using non-linear regression on Prism 4.0 GraphPad
6432 J. M. dos Santos Filho et al. / Bioorg. Med. Chem. 20 (2012) 6423–6433software. This experiment was done in triplicate, and benznidazole
(LAFEPE, Pernambuco, Brazil) was used as the reference inhibitor.
4.7. Cytotoxicity for trypomastigotes
Trypomastigotes collected from the supernatants of LLC-MK2
cells were dispensed into 96-well plates at a cell density of
4  105 cells/well. Test inhibitors, dissolved in DMSO, were diluted
into ﬁve different concentrations and added into their respective
wells, and the plate was incubated for 24 h at 37 C and 5% of
CO2. Aliquots of each well were collected and the number of viable
parasites, based on parasite motility, was assessed in a Neubauer
chamber. The percentage of inhibition was calculated in relation
to untreated cultures. IC50 calculation was also carried out using
a non-linear regression with Prism 4.0 GraphPad software. This
experiment was repeated once, and benznidazole was used as
the positive control.
4.8. Trypomastigote development
Peritoneal exudate macrophages were seeded at a cell density
of 2  105 cells/well in a 24 well-plate with rounded coverslips
on the bottom in RPMI supplemented with 10% FBS and incubated
for 24 h. Cells were then infected with trypomastigotes at a ratio of
10 parasites per macrophage for 2 h. Free trypomastigotes were re-
moved by successive washes using saline solution. Each test inhib-
itor was dissolved in DMSO at 10 lg/mL and incubated for 6 h. The
medium was replaced by a fresh medium and the plate was incu-
bated for 4 days. Cells were ﬁxed in methanol and the percentage
of infected macrophages and the mean number of amastigotes/in-
fected macrophages was determined by manual counting after
Giemsa staining in an optical microscope (Olympus, Tokyo, Japan).
The percentage of infected macrophages and the number of
amastigotes per macrophage was determined by counting 100 cells
per slide.
4.9. Trypomastigote invasion
Peritoneal macrophages (105 cells) were plated onto 13-mm
glass coverslips in 24-well plate and kept for 24 h. The plate
was washed with saline solution and then trypomastigotes were
added at a cell density of 1.25  107 along with the addition of
test inhibitor (stock solution at 10 lg/mL). The plate was incu-
bated for 2 h at 37 C and 5% CO2, followed by ﬁve washes with
saline solution to remove extracellular trypomastigotes. Plates
were maintained in RPMI medium supplemented with 10% FBS
at 37 C for 2 h. Infected cells were examined for the presence
of amastigotes by optical microscopy using a standard Giemsa
staining.
4.10. Ultrastructural studies
Trypomastigotes at a cell density of 3  107 were treated with
test inhibitors 6c (9.5 lM) and 6d (3.5 lM) for 24 h. Parasites
were then ﬁxed with 2% formaldehyde and 2.5% glutaraldehyde
(Electron Microscopy Sciences, PA, USA) in sodium cacodylate
buffer (0.1 M, pH 7.2) for 1 h at room temperature. After ﬁxation,
parasites were washed three times with sodium cacodylate buf-
fer (0.1 M, pH 7.2), and post-ﬁxed with a 1.0% solution of os-
mium tetroxide (Sigma Chemical Co., MO, USA) for 1 h. Cells
were subsequently dehydrated in increasing concentrations of
acetone (30%, 50%, 70%, 90% and 100%) for 10 min at each step
and embedded in resin Polybed (PolyScience family, Warrington,
PA, USA). Ultrathin sections were prepared on an ultramicrotome
Leica UC7 and sections were collected on copper grids of 300
meshes, contrasted with uranyl acetate and lead citrate and ob-served under a JEOL TEM-1230 transmission electron micro-
scope. For scanning electron microscopy, trypomastigotes
treated with 6c (30 lM) or 6d (10 lM) and ﬁxed in the same
conditions were washed in 0.1 M cacodylate buffer, and allowed
to adhere in coverslips pre-coated with poly-L-lysine (Sigma Co.).
After adherence, cells were post-ﬁxed with a solution of osmium
tetroxide containing 0.8–1% of potassium ferrocyanide for
30 min. Cells were subsequently dehydrated in the presence of
increasing concentrations of ethanol (30%, 50%, 70%, 90%, and
100%) during 15 min each step, and then subjected to the critical
point, metallized with gold and analyzed in a JEOL JSM-6390LV
scanning electron microscope. The same procedure was per-
formed for TEM in infected macrophages treated with compound
6d.
4.11. Toxicity in mice
Female BALB/c mice (6–8 weeks old; n = 3/group) were orally
treated with oxadiazole 6d at doses of 100, 50 and 25 mg/kg. Ani-
mals were monitored for signs of general toxicity, including behav-
ior and feeding, until 24 h after treatment. Heparinized blood
samples were collected after 24 h of treatment, centrifuged for
3 min. to separate out from cells and then serum components were
analyzed using Analyst (Hemagen, Columbia, USA) platform
system.
4.12. Infection in mice
Female BALB/c mice (6–8 weeks old) were infected with blood-
stream trypomastigotes by intraperitoneal inoculation of 104 para-
sites in 100 lL of saline solution and then mice were divided in
groups (six animals per group). After the day 5 of infection, treat-
ment with 50 mg/kg weight of drugs 6c and 6d was given orally
for ﬁve consecutive days. For the control group, Benznidazole
was given orally at dose of 100 mg/kg weight. Animal infection
was monitored daily by counting the number of motile parasites
in 5 lL of fresh blood sample drawn from the lateral tail veins as
recommended by standard protocols.33
4.13. Statistical analyses
To determine the statistical signiﬁcance of each group in the
in vitro/in vivo experiments, the one-way ANOVA test and the Bon-
ferroni for multiple comparisons were used. A p value <0.05 was
considered of statistical signiﬁcance. The data are representative
of at least two or three experiments ran in triplicate.
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